SG11201906001RA - Compositions and methods for treating iron overload - Google Patents
Compositions and methods for treating iron overloadInfo
- Publication number
- SG11201906001RA SG11201906001RA SG11201906001RA SG11201906001RA SG11201906001RA SG 11201906001R A SG11201906001R A SG 11201906001RA SG 11201906001R A SG11201906001R A SG 11201906001RA SG 11201906001R A SG11201906001R A SG 11201906001RA SG 11201906001R A SG11201906001R A SG 11201906001RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- hepcidin
- iron overload
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) omit m illOIDEMIME1101100111110#011 (10) International Publication Number WO 2018/136636 Al WIPO I PCT (51) International Patent Classification: A61K 38/22 (2006.01) A61P 7/06 (2006.01) A61K 38/17 (2006.01) A61P 13/12 (2006.01) A61K 38/10 (2006.01) A61P 3/00 (2006.01) A61K 38/08 (2006.01) A61K 38/16 (2006.01) (21) International Application Number: PCT/US2018/014241 (22) International Filing Date: Published: — with international search report (Art. 21(3)) (25) Filing Language: (26) Publication Language: (30) Priority Data: 18 January 2018 (18.01.2018) English English 1-1 00 62/447,710 18 January 2017 (18.01.2017) US 62/454,322 03 February 2017 (03.02.2017) US 62/554,115 05 September 2017 (05.09.2017) US (71) Applicant: LA JOLLA PHARMACEUTICAL COM- PANY [US/US]; 4550 Towne Center Court, San Diego, CA 92121 (US). (72) Inventors: TIDMARSH, George; 45 Tintern Lane, Porto- la Valley, CA 94028 (US). CHAWLA, Lakhmir; 10586 Abalone Landing Ter, San Diego, CA 92130 (US). (74) Agent: HALSTEAD, David, P. et al.; Foley Hoag LLP, 155 Seaport Boulevard, Boston, MA 02210-2600 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) (54) Title: COMPOSITIONS AND METHODS FOR TREATING IRON OVERLOAD (57) : The present disclosure relates to the use of hepcidin, mini-hepcidin, or a hepcidin analogue in therapeutic methods for the treatment and/or prevention of acquired iron overload or other conditions for which iron redistribution or sequestration is helpful.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447710P | 2017-01-18 | 2017-01-18 | |
| US201762454322P | 2017-02-03 | 2017-02-03 | |
| US201762554115P | 2017-09-05 | 2017-09-05 | |
| PCT/US2018/014241 WO2018136636A1 (en) | 2017-01-18 | 2018-01-18 | Compositions and methods for treating iron overload |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906001RA true SG11201906001RA (en) | 2019-08-27 |
Family
ID=62908242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906001RA SG11201906001RA (en) | 2017-01-18 | 2018-01-18 | Compositions and methods for treating iron overload |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190336583A1 (en) |
| EP (1) | EP3570873A1 (en) |
| JP (1) | JP2020504160A (en) |
| CN (1) | CN110520147A (en) |
| AU (1) | AU2018210166A1 (en) |
| BR (1) | BR112019014524A2 (en) |
| CA (1) | CA3049977A1 (en) |
| IL (1) | IL267908A (en) |
| MA (1) | MA47322A (en) |
| MX (1) | MX2019007325A (en) |
| PH (1) | PH12019501631A1 (en) |
| SG (1) | SG11201906001RA (en) |
| WO (1) | WO2018136636A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022001063A2 (en) * | 2019-07-19 | 2022-03-15 | Vifor Int Ag | Ferroportin inhibitors for use in the prevention and treatment of kidney injury |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2569631A4 (en) * | 2010-05-10 | 2013-12-04 | Austin Health | Markers for acute kidney injury |
| PL2968443T3 (en) * | 2013-03-15 | 2022-02-07 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| US9981012B2 (en) * | 2013-09-20 | 2018-05-29 | University Of Virginia Patent Foundation | Compositions and methods for protecting the kidney from ischemia reperfusion injury |
| US20170246256A1 (en) * | 2016-01-08 | 2017-08-31 | La Jolla Pharmaceutical Company | Methods of administering hepcidin |
-
2018
- 2018-01-18 JP JP2019538184A patent/JP2020504160A/en active Pending
- 2018-01-18 CN CN201880014845.2A patent/CN110520147A/en active Pending
- 2018-01-18 BR BR112019014524-9A patent/BR112019014524A2/en not_active Application Discontinuation
- 2018-01-18 EP EP18742291.0A patent/EP3570873A1/en not_active Withdrawn
- 2018-01-18 AU AU2018210166A patent/AU2018210166A1/en not_active Abandoned
- 2018-01-18 WO PCT/US2018/014241 patent/WO2018136636A1/en unknown
- 2018-01-18 MX MX2019007325A patent/MX2019007325A/en unknown
- 2018-01-18 US US16/478,998 patent/US20190336583A1/en not_active Abandoned
- 2018-01-18 CA CA3049977A patent/CA3049977A1/en not_active Abandoned
- 2018-01-18 SG SG11201906001RA patent/SG11201906001RA/en unknown
- 2018-01-18 MA MA047322A patent/MA47322A/en unknown
-
2019
- 2019-07-08 IL IL267908A patent/IL267908A/en unknown
- 2019-07-12 PH PH12019501631A patent/PH12019501631A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12019501631A1 (en) | 2020-03-09 |
| MA47322A (en) | 2019-11-27 |
| BR112019014524A2 (en) | 2020-02-27 |
| AU2018210166A1 (en) | 2019-07-25 |
| JP2020504160A (en) | 2020-02-06 |
| US20190336583A1 (en) | 2019-11-07 |
| WO2018136636A1 (en) | 2018-07-26 |
| CN110520147A (en) | 2019-11-29 |
| IL267908A (en) | 2019-09-26 |
| CA3049977A1 (en) | 2018-07-26 |
| MX2019007325A (en) | 2019-09-02 |
| EP3570873A1 (en) | 2019-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906958TA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201900651PA (en) | Combination of fxr agonists | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction |